Please note: The license is valid for 12 months from the date the report is sent.
Contract manufacturing for pharma – discover top companies’ revenue prospects
How are pharma contract manufacturing organisations (CMOs) performing? Visiongain’s new report shows you their prospects to 2024. There you discover that industry and market’s results, trends, opportunities and prospects, also with predicted revenues and profits.
Our study analyses 30 top CMOs. There you see how revenues from drug production services can increase. So what trends, technologies and opportunities most shape the future? You find out, benefiting your knowledge, decisions and authority.
That way you discover analysis on established and emerging companies across the world. Read on, then, to scan those organisations and see what their future market could be worth.Forecasts and other data to help you stay ahead for commercial data
In that updated study you find analytical profiles of 30 top companies, and analyses of their overall industry. You discover historical data, market and sales shares, growth rates and revenue forecasts. See, too, qualitative analyses, business outlooks and developments.
There you gain 184 tables, 111 charts and five interviews with that industry.
Our work lets you assess the most lucrative services in outsourced drug making. That way you can stay ahead in understanding the CMO industry and market. And also benefit your research, analyses and influence. In particular, see prospects for these market segments:
- Active pharmaceutical ingredients (API) production
- Finished dosage formulations (FDF) manufacturing.
There hear how you can benefit your work, also saving time and helping you stay ahead of competitors. And the following sections highlight what our updated investigation gives you.Company profiles – activities, results, competition and prospects
Our report analyses 30 leading companies. The content of each profile differs, depending on the organisation. In general, though, a profile gives you the following information:
- Overview of the company’s contract manufacturing services, including clients
- Analysis of recent financial performance – annual revenue for CMO services, operating profit and margin
- Assessment of developments – activities, acquisitions, production capacity, deals, new service offerings and collaborations
- SWOT analysis – a firm’s strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2014 onwards
- Forecasting of pharmaceutical manufacturing revenue to 2024 (for 28 firms), as well as projected operating profit and margin for some companies
- Transcript of an interview by visiongain (for five companies).
Discover there what participants offer, achieve, aim for and say, helping you stay ahead.European contract manufacturing organisations
First our study gives you discussions, financial analyses and commercial outlooks for 14 European CMOs, including these firms:
- Evonik Degussa
- Royal DSM
- Boehringer Ingelheim
- Vetter Pharma.
Discover what the future holds for those pharma service providers, including revenue outlooks to 2024. What profitability and other achievements are possible?CMOs based in the US and Japan
Next our report shows you developments and business outlooks for seven other medical production contractors:
- Catalent Pharma Solutions
- Baxter BioPharma Solutions
- AbbVie Contract Manufacturing
- Pfizer CentreSource
- Daito Pharmaceutical
- Nipro Corporation.
Our work shows you where sales growth can occur. Many opportunities remain, with high, expanding revenues forecasted from 2014. You discover where prospects exist, seeing what’s possible.
Developed-market API specialists
You also discover outlooks for three top producers of active pharmaceutical in
Get Industry Insights. Simply.
- Latest reports & slideshows with insights from top research analysts
- 60 Million searchable statistics with tables, figures & datasets
- More than 25,000 trusted sources